Andrea Casadei‐Gardini

Author

Istituti di Ricovero e Cura a Carattere Scientifico ORCID

Also Known As

A Gardini, A. Casadei Gardini, A. Casadei-Gardini, A. Casadei-gardini, A. Gardini, A., Casadei-Gardini, A.C. Gardini, ANDREA CASADEI-GARDINI, Adelaida Lacasta, Andrea Casadei Gardini

474

Publications

7.4K

Citations

H-Index

Concepts

All Affiliations

Istituti di Ricovero e Cura a Carattere Scientifico Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori University of Cagliari Vita-Salute San Raffaele University University of Modena and Reggio Emilia

About

Andrea Casadei‐Gardini is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in medicine, oncology, and hepatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	47	2K
2	Health Sciences	12	15	394
3	Nursing	3	3	371
4	Engineering	1	1	58
5	Biomedical Engineering	1	1	58

Andrea Casadei‐Gardini

138

Publications

Citations

H-Index

Page 1

	Year	Citations
Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life Marco Maltoni, Emanuela Scarpi, Monia Dall’Agata, European Journal of Cancer NursingFamily MedicinePalliative CareEnd-of-life CareSymptomatic Treatment	2016	182
Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial Marco Maltoni, Emanuela Scarpi, Monia Dall’Agata, European Journal of Cancer Palliative CareNursingFamily MedicineSystematic VersusEnd-of-life Care	2016	170
In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3–Mediated Apoptosis Francesca Fornari, Daniela Pollutri, Clarissa Patrizi, Clinical Cancer Research	2017	170
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis Margherita Rimini, Lorenza Rimassa, Kazuomi Ueshima, ESMO Open	2022	124
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population Andrea Casadei‐Gardini, Margherita Rimini, Toshifumi Tada, European Journal of Cancer OncologyHepatologyMedicinePathologyBevacizumab Versus Lenvatinib	2022	123
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data Margherita Rimini, Lorenzo Fornaro, Sara Lonardi, Liver International	2023	110
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib Andrea Casadei‐Gardini, Emanuela Scarpi, Luca Faloppi, Oncotarget PrognosisImmunologyPathologySystemic Immune-inflammation IndexAdvanced Hcc Patients	2016	94
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale Andrea Casadei‐Gardini, Luca Faloppi, Serena De Matteis, European Journal of Cancer OncologyHepatologyHepatocellular CarcinomaPathologyLiver Disease	2017	92
Shifts of Faecal Microbiota During Sporadic Colorectal Carcinogenesis Giorgia Mori, Simone Rampelli, Béatrice Silvia Orena, Scientific Reports	2018	89
Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients Francesco Tovoli, Luca Ielasi, Andrea Casadei‐Gardini, Journal of Hepatology Adverse EventsHepatologyHepatocellular Carcinoma PatientsMedicinePharmacotherapy	2019	84

Page 1